A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmacyclics LLC.
• Treatments: Motexafin gadolinium

Criteria

Inclusion Criteria:

• At least 18 years old

• Refractory or relapsed CLL

• ECOG performance status score of 0, 1, or 2

• Each patient must sign a study-specific informed consent form

Exclusion Criteria:

Laboratory values of:

• Platelet count <30,000/uL

• AST or ALT >2 x the upper limit of normal (ULN)

• Total bilirubin >2 x ULN

• Creatinine >2.0 mg/dL

• Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment

• Women who are pregnant or lactating